Athenex announced that collaborators at the Quantum Leap Healthcare Collaborative reported that the Company’s oral paclitaxel plus encequidar in combination with a PD-1 inhibitor and carboplatin has graduated in the triple-negative subgroup of high-risk early-stage breast cancer. Oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia. Quantum Leap Healthcare Collaborative anticipates presenting these results at upcoming national meetings in Q2 of 2023. "We are very pleased that the Oral Paclitaxel combination regimen graduated from this prestigious program which has brought exciting and innovative treatments to neoadjuvant breast cancer patients. This study confirms our finding of less neuropathy for Oral Paclitaxel compared to intravenous paclitaxel in our metastatic breast cancer study. It’s reassuring to see that Oral Paclitaxel regimen was not associated with increased febrile neutropenia relative to the intravenous paclitaxel regimen in a well-conducted U.S. study," said Dr. Johnson Lau, CEO of Athenex. "We will explore different opportunities to maximize the value of Oral Paclitaxel."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ATNX:
- Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
- Athenex exits 503B sterile compounding business
- Athenex Exits 503B Sterile Compounding Business
- Athenex Announces Positive Results of Special Stockholder Meeting
- Athenex Announces Closing of the Sale of its China API Business